SUBSTI	20	EORM P	·TO	-144	9						ENT OF COMMERCE FRADEMARK OFFICE	ATTY. PMAN	DOCKET NO /25	D.	10/667	NL NO. 7,161
,,,,	23	3006 "	)				-			OSURE LICANT		APPLI Gholai	CANT n Peyman			
(SECFR	1.98(t	o))		(Us	e se	vera	al st	neet	s if ne	ecessary)			DATE nber 19, 200	3	GROL 1615	JP
1988	FRAD									U.S. F	PATENT DOCUMENTS					
EXAMINE	R									ISSUE						FILING DATE
- INITIAL			+-	Τ		NT N	Г	Т	Г	DATE	PATENTEE		CLASS	SUBC	LASS	IF APPROPRIATE
<u> </u>		A.A	4	0	7	9	0	3	8	03/14/78	Choi et al		260	47		03/05/76
		A.B	4	0	9	3	7	0	9	06/06/78	Choi et al		424	19		01/28/75
		A.C	4	1	3	-	6	4	8	12/26/78	Choi et al		424	22		03/02/78
		A.D	4	1	3	8	3	4	4	02/06/79	Choi et al		252	1		08/24/77
		A.E	4	1	8	0	6	4	6	12/25/79	Choi et al	···	528	153		03/03/78
		A.F	4	3	0	4	7	6	7	12/08/81	Heller et al		424	78		05/15/80
	A.G 4 9 4 6 9 3 1 08/07/90 Heller et al 528 320 06/14/89  A.H 5 4 2 9 4 6 9 0 03/15/94 Nussenblatt et al 514 11 12/20/89  A.I 5 3 8 7 5 8 9 02/07/95 Kulkarni 514 291 11/17/92															
	A.H 5 2 9 4 6 0 4 03/15/94 Nussenblatt et al 514 11 12/20/89															
	A.H 5 2 9 4 6 0 03/15/94 Nussenblatt et al 514 11 12/20/89  A.I 5 3 8 7 5 8 9 02/07/95 Kulkarni 514 291 11/17/92  A.J 5 4 1 1 9 6 2 05/1995 Kaswan															
	A.1 5 3 8 7 5 8 9 02/07/95 Kulkarni 514 291 11/17/92															
A.J 5 4 1 1 9 6 2 05/1995 Kaswan  A.K 5 4 5 7 1 8 2 10/10/95 Wiederrecht et al 530 402 02/15/94																
7	A.J 5 4 1 1 9 6 2 05/1995 Kaswan															
	A.J 5 4 1 1 9 6 2 05/1995 Kaswan  A.K 5 4 5 7 1 8 2 10/10/95 Wiederrecht et al 530 402 02/15/94															
9		A.L	wc	00 0	/66	122			11/	09/00	per Wo		A61K	31/436		N/A
	8	A.M	wc	02	/08	5928	3		10/	31/02	pet WO		C07K	7/54 ·		Abstract only
ð	8	A.N	wc	20	04/	0143	373		02/	19/04	per WO		A61K	31/436		N/A
8		A.O	EP	107	425	55			02/	07/01	EP		A61K	31/40		N/A
98		A.P	WC	99	/34	330			07/	15/99	per WO		A61K	47/18		N/A
	-L	A.Q	AU	473	386/	88			Uni	nown	AU AIO L	1776		Unknow	,	N/A ·
						0	THE	ER (	ocu	JMENTS (Inclu	uding Author, Title, Date		of Publication	)		
(X)	3	A.R								tcome of RPE :217-230	allografts in non-immun	osuppre	ssed patients	with AMI	O, Europ	pean J of
0/8		A.S	And Opt	ders htha	on e	et al	., <u>A</u>	Role	e for I 34, N	Local Inflamma	ation in the Formation o er 2002, pp. 411-431	f Drusen	in the Aging	Eye, Ame	erican J	ournal of
4	8	A.T				<u>A s</u> 7, 19		onju	nctiv	al degradable i	implant for cyclsoprine	delivery i	n ∞rneal trai	splant th	erapy, C	Curr. Eye Res.
EXAMINI	ER	(	W.	/ wr	X	10	۲.	<i>\[ \]</i> -	() R	eu D	DATE CONS	IDERED	02/8	3/0	6	
EXAMINE Include a	ER: Ini	itial if cit	atior	n co	nsid	lered	d, w	heti	ner or	not in conform to applicant.	nance. Draw line throug	h citatio	n only if not i	n conform	ance <u>ar</u>	nd not considered.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE (MODIFIED)	FORM F	PTO-	144	9						ENT OF COMMERCE TRADEMARK OFFICE	ATTY. PMAN	DOCKET NO 25	Э.	SERIA 10/667	
									OSURE LICANT		APPLIC Gholan	CANT n Peyman			
(37 CFR 1.98	(b))		(Us	e se	ver	al st	neet	s if ne	ecessary)		FILING Septen	DATE nber 19, 200	3	GROU 1615	IP
									U.S. I	PATENT DOCUMENTS					
EXAMINER INITIAL			PA	TEN	NT N	IUM	IBEI	₹	ISSUE DATE	PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
als	B.A	5	7	7	0	6	0	7	06/23/98	Honbo et al		514	302		07/18/94
. 1/1	B.B	5	7	7	3	0	1	9	06/30/98	Ashton et al		424	423		09/27/95
	B.C	5	9	5	2	3	7	1	09/14/99	Baker et al		514	443		10/08/97
	B.D	5	9	6	8	5	4	3	10/19/99	Heller et al		424	425		12/05/97
	8.E	6	0	0	4	5	6	5	12/21/99	Chiba		424	278.1		09/23/97
B.F 6 3 3 1 3 1 3 12/2001 Wong et al — — — — — — — — — — — — — — — — — —															
B.G 6 3 5 0 4 4 2 02/26/02 Garst 424 78.04 05/30/2001  B.H 6 4 6 2 0 7 1 10/2002 Castillejos															05/30/2001
B.G 6 3 5 0 4 4 2 02/26/02 Garst 424 78.04 05/30/2001  B.H 6 4 6 2 0 7 1 10/2002 Castillejos — — — — — — — — — — — — — — — — — — —															
B.G 6 3 5 0 4 4 2 02/26/02 Garst 424 78.04 05/30/2001  B.H 6 4 6 2 0 7 1 10/2002 Castillejos															
B.G 6 3 5 0 4 4 2 02/26/02 Garst 424 78.04 05/30/2001  B.H 6 4 6 2 0 7 1 10/2002 Castillejos															08/04/00
B.H 6 4 6 2 0 7 1 10/2002 Castillejos  B.I 6 4 8 2 7 9 9 11/2002 Tuse et al  B.J 6 5 0 6 2 0 6 07/22/03 Nelson et al 424 426 08/04/00															01/31/01
7	B.I 6 4 8 2 7 9 9 11/2002 Tuse et al														
	B.J 6 5 0 6 2 0 6 07/22/03 Nelson et al 424 426 08/04/00  B.K 6 5 3 4 6 9 3 03/18/03 Fischell et al. A61F 13/00 01/31/01														
	B.L.	للف	203	350/	92			Uni	(nown	ALL NO DA	TE		Unknowr	1	N/A
0/8	в.м	CN	133	3301	18			01/	30/02	CN		A61K	9/06		Abstract only
V <sub>j</sub>	B.N	CN	134	1035	58			03/	20/02	CN		A61K	38/13		Abstract only
	В.О	CN	145	635	50			11/	19/03	CN		A61K	9/00		Abstract only
	B.P	DE	198	3108	555			09/	16/99	DE		A61K	38/13		Abstract only
QXS	B.Q	EP	114	25€	66			10/	10/01	EP		A61K	9/08		Abstract only
- V					0	тн	ER (	DOCI	JMENTS (Ind	uding Author, Title, Date	, Place o	f Publication	)		
al	B.R	Ara	ma	nt e	tal,	Ret	inal	trans	plantation, Sc	ience & Medicines (2000	0), 7:20-2	9			
0/8	B.S								sporin A on the 43-248	e blood-retinal barrier pe	ermeabilit	y in streptoz	otocin-ind	uced dia	abetes, Mediators of
98	В.Т	wit	ou, h Or 10/0	hth	ical alm	Tre	atm om	ent o ulatio	f Ocular Hype n of Dopamine	rtension, Glaucoma, Isc e Antagonists, U.S. Pate	hemic Re ent Applic	etinopathy an ation Publica	d Age-Reation No.	lated M US 203/	acular Degeneration 0069232, published
EXAMINER	Qu	M	'LI	a	. ?	1	I	ne	ill	DATE CONS	IDERED	00	423	106	
EXAMINER: I	nitial if ci	tatio	n co	nsic	tere	d, w	het	her o	not in confor	mance. Draw line throug	gh citation	n only if not i	n conform	ance <u>ar</u>	not considered.

Sheet 3 (C) of 15

SUBSTITUTE (MODIFIED)	FORM F	PΤΟ	-144	9				U.	S. DEPARTM	ENT OF COMMERCE TRADEMARK OFFICE	ATTY. PMAN	DOCKET N /25	0.	SERI/ 10/66	AL NO. 7,161
•				-					OSURE LICANT		APPLI Gholar	CANT n Peyman			
(37 CFR 1.98	(b))		•	e se `	even	al s	heel	s if no	ecessary)			DATE nber 19, 200	3	GROU 1615	JP
				•					U.S. F	PATENT DOCUMENTS					
EXAMINER INITIAL			PA	TEI	NT N	AUN	18E	R	ISSUE DATE	PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
0/8	C.A	6	6	1	3	3	5	5	09/02/03	Ng et al		424	462		05/11/01
. 1	С.В	6	6	1	7	3	4	5	09/09/03	Gregory et al		514	395		09/12/00
	C.C	6	6	6	7	3	7	1	12/23/03	Ng et al		525	462	-	11/14/02
	C.D	6	6	7	0	3	9	8	12/2003	Edwards et al			_	•	
	C.E	6	6	7	3	8	0	7	01/2004	Sakai et al			_		
0/1	C.F 6 7 1 3 0 8 1 03/2004 Robinson et al														
	C.F 6 7 1 3 0 8 1 03/2004 Robinson et al														
	C.G C.H C.I														
	C.F 6 7 1 3 0 6 1 05250 RODIISDI et al														
	C.G C.H C.I C.J C.K														
•	C.H														
	C.I														
1	C.H  C.I  C.J  C.K  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS														
$\bigcirc$	C.L	JP	10-2	218	787			08/	18/98	JP		A61K	38/22		Yes
7,	C.M	JP	199	703	096	6		02/0	04/97	JP		A61K	31/365		Yes
	C.N	JP	200	1-0	6419	98		03/	13/01	JP		A61K	38/22		Yes
	C.O	wc	02	/24	234			03/2	28/02	PET- WO		A61K	48/00		N/A
$\frac{1}{2}$	C.P	wc	03	/05 <sup>-</sup>	1385	5		06/	26/03	PCT WO		A61K	38/13		Abstract only
	C.Q	wc	03	/01	7990	)		03/0	06/03	PCI WO		A61K	31/00		N/A
V					0	тн	ER (	OOCL	JMENTS (Inclu	uding Author, Title, Date	, Place o	f Publication	)	,	
ak	C.R								netics of subc /2001), 42(4):5	onjunctivally administere	d cylcos	porine A. Lo	ocal delive	ry prior	to chemotherapy for
OB	c.s									and GDNF Enhance No gy 164,60-60 (2000)	eurite Bra	enching or E	longation	from De	eveloping Dopamine
98	C.T									etal neuroretinal cells in y (1999), 157:58-68	advance	d retinitis pig	mentosa	patients	: Results of a long-
EXAMINER	Qu	un	u	a	ر ر	1	J.	lu		DATE CONSI	DERED	02/	23/0	6	
EXAMINER: I Include a cop	nitial if cit	atior	100	nsic	tere	d, w				nance. Draw line throug	h citation	only if not i	n conform	ance <u>ar</u>	nd not considered.

SUBSTITUT	E EORM	DTO.	144	٥					S DEPART	IME	NT OF COMMERCE	ATT	. DOCKET N	10		et 4 (D) of 15 AL NO.
(MODIFIED)		-10-	144	9				P	ATENT AN	D TF	RADEMARK OFFICE	PMA		····	10/66	
									OSURE LICANT				ICANT am Peyman			
(37 CFR 1.9	8(b))	(	(Use	se'	vera	al sh	eet	s if n	ecessary)		_		G DATE ember 19, 20	03	GROU 1615	JP
									U.S	S. P/	ATENT DOCUMENTS		-		•	
EXAMINER INITIAL			PAT	ΓEN	TΝ	UM	BEF	₹	ISSUE DATE		PATENTEE		CLASS	SUBC	LASS	FILING DATE IF APPROPRIATE
	D.A									1						
	D.B	T				_			ļ- · · · · · · · · · · · · · · · · · · ·	十			<u> </u>			
	D.C	$\top$	П							T						
	D.D	$\top$								1		/	1			
	D.E	$\top$								1						
	D.F	$\top$								1						
	D.G	$\top$			٦					1						
	D.H	$\Box$		$\neg$	寸					十				Ì		
	D.I	$\sqcap$		7	7					T						
•	D.J.	77								1						
	D.K	П										*				
•					FO	REI	GN	PAT	ENTS OR P	UBL	ISHED FOREIGN PA	TENT A	PPLICATION	NS		
,			DO( N)	CUM				PI	UBLICATION DATE	N	COUNTRY OF PATENT OFFIC		CLASS	SUBCL	ASS	TRANSLATION (YES/NO)
∩\\	D.L	wo	200	)4/0	962	61		11/	11/04		PCT WO		A61K	38/13		Abstract only
4,	D.M	wo	200	)4/0-	434	80		05/2	27/04		PCI WO		A61K	38/00		N/A
	D.N	wo	200	)5/0	302	05		04/0	07/05		PCT WO		A61K	31/436		N/A
	D.O	wo	200	)5/0	118	13		02/	10/05		Per WO		A61P	27/02		N/A
1/2	D.P	wo	89/	017	72			03/0	09/89		PCT WO		A61K	9/00		N/A
(1)()	D.Q	wo	99/	4210	04			08/2	26/99		PGT WO		A61K	31/435		N/A
V					01	THE	R D	OCL	IMENTS (In	clud	ing Author, Title, Date		of Publication	n)		
0/3	D.R	Del (200							orrelation of	hun	nan neural retinal trans	plantat	ion, Invest. C	phthalmol	ogy & V	isual Science
db	D.S	Don	nen	feld	et a	ıļ., <u>C</u>	Cycl	ospo	rine provide	s eff	ective treatment for dr	<u>y eye,</u> 1	Therapeutic (	Jpdates in	Ophthal	mology, Special

D.S Donnenfeld et al., Cyclosporine provides effective treatment for dry eye, Therapeutic Updates in Ophthalmology, Special Issue, July 1999, pp. 1-3

D.T Enyedi et al., Pharmacokinetics and toxicity of an intravitreal device providing sustained release of cyclosporine (CsA) and dexamethasone (DEX), Invest. Ophthalmology and Visual Science, Vol. 35, No. 4, 1994, p. 1906, and Annual Meeting of the Association for Research in Vision and Ophthalmology, Sarasota, FL, USA, May 1-6, 1994, abstract

EXAMINER JUNE 1 DATE CONSIDERED 02/23/06

EXAMINER: Initial it citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 5 (E) of 15

SUBSTITUTE (MODIFIED)	FORM	PTO-	-144	9				U.S.	. DEF	PARTM AND 1	ENT O	F COM	MERCE OFFICE		ATTY.	DOCK 25	ET N	0.		SERIA 10/667			
									SURI						APPLI	CANT n Peyr	nan						
(37 CFR 1.98	(b))		(Us	e se	vera	al she	ets i	i neci	essaı	y)						DATE		13		GROU 1615	JP		
			`							U.S. F	PATEN	T DOC	UMENTS										
EXAMINER INITIAL			PA	TEN	ŧT N	IUME	ER		ISS DA	UE TE		PA	TENTEE			CL	ASS	sui	всі	ASS		FILING DAT	
	E.A			Γ		П	T										•						
	E.B	1				П	T														Γ		
	E.C	Т		Γ		П	T														Π		
	E.D	Τ				П	T							_									
	E.E		Γ	Γ				T															
	E.F	Τ				П		T									· · · · · · · · · · · · · · · · · · ·				Γ		
	E.G																						
	E.H																						
	E.I																						
•	الاع																						
	E.K																						
•																							
					MEN BER				BLICA	TION E			INTRY OF			CLAS	ss	SUB	CLA	ss	Т	RANSLATIC (YES/NO)	
	E.L																			$\neg \neg$			
	E.M														7								
	E.N																						
	E.O								_														
	E.P				_	_	7															:	
	E.Q																						
,					0	THE	R DO	CUM	ENT	S (Indi	iding A	uthor,	Title, Date	e, P	lace o	f Publi	cation	)					
$\alpha/2$	E.R						avitre 49-5		evicé	providi	n susta	ined re	lease of c	yd	sporin	e and	dexan	nethaso	one,	Curr. E	Eye I	Res. May 19	196,
3/3	E.S	Gai	weg nats	g et blat	al, <u>T</u> ter f	hera ur Au	py of gent	Gold	<u>iman</u> inde,	n-Favre Vol., 1	e's Vitn 99, No	eo-Reti . 3, Sep	nal Deger otember 1	<u>1991</u>	ation w	rith Cy 199-20	dospo 5	orin A a	nd l	Bromod	ripti	ne, Klinische	)
OXX	E.T	Gill	ard	, <u>E</u> \	V In	tervie	w: E	lectro	olyte	balance	is key	to dry	eye prodi	uct'	s succ	<u>ess,</u> E	yeWo	rld, Fel	brua	ıry 200	0, pp	). 20ff	
EXAMINER	Oh	unl	u	a	7/	1.0	rei	W	0			DA	TE CONS	IDE	ERED		0=	2/5	3	100	, 0		
EXAMINER: I	nitial if ci	tation	00	nsid	erec	i, wh	ether	or no	ot in e		nance.	Draw	line throug	gh d	citation	only i	f not i	n confo	ma	nce <u>ar</u>	<u>id</u> no	ot considered	J.

SUBSTITUTE (MODIFIED)	FORM	PTO-	-144	9									COMMI		ATTY.		KET N	0.	SERIA 10/667	AL NO. 7,161
			INI ST	FOR TATE	MA` ME	TIOI NT	N D BY	ISCL APP	OSU LICA	JRE ANT					APPLI Ghola			-		
(37 CFR 1.98	(b))		(Us	e se	vera	ıl sh	eets	s if n	eces	sary)					FILING Septe			)3	GROU 1615	JP
										U.S	S. PA	TENT	DOCUM	MENTS						
EXAMINER INITIAL			PA	TEN	TN	UM	BEF	₹		SSUE DATE	T		PATE	NTEE		CL	ASS	SUBC	CLASS	FILING DATE IF APPROPRIATE
	F.A																			
	F.B	1	Τ	П							1						-			
	F.C	T		П																
	F.D	T		П							$\top$									
	F.E	Τ		П							$\top$									·
	F.F F.G F.H																			
	F.G									$\overline{Z}$										
	F.H																			
	F.I					4														
•	F.J									····						ļ				
	F.K	1							<u> </u>						<u></u>			<u></u>		
•		F.E  F.F  F.G  F.H  F.J  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  DOCUMENT PUBLICATION COUNTRY OR TRANSLAY																		
	F.G  F.H  F.I  F.J  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICA  DOCUMENT PUBLICATION COUNTRY OR															ss	SUBC	ASS	TRANSLATION (YES/NO)	
	F.L																			
	F.M													_						
	F.N											_	_							
	F.O			<del>,</del>					_									_		
	F.P				_	_	4													· · · · · · · · · · · · · · · · · · ·
	F.Q			_	_															
06	r				0	THE	RC	OCI	UME	NTS (Ir	ndudi	ng Au	thor, Tit	e, Date	, Place	of Pub	lication	1)		
(1/8)	F.R	Gri	sola	no e	t al.	, <u>R</u> e	tina	l To	xicity	Study	of Int	ravitre	al Cydo	sporin,	Opthaln	nic Su	rgery,	March 19	36, 17:15	55-156
02	F.S	Ha: Pul	gem blica	an e	t al. No.	, <u>Di</u>	agn 200	ostic 02/00	s and 0159	<u>d Thera</u> 57, pub	apeuti olished	cs for d 02/0	Macutai 7/02,	Deger	eration-	Relate	d Diso	rders, U.	S. Paten	t Application
OS.	F.T	Jia Ro	ng e yal (	t al, Colle	Cor ge c	nea of St	l ele urge	ectro	retino	ographi Invest	c fund	ction re	escued ology &	oy nom Visual :	nal retina Science	al pign (1994)	nent ep ), 35(1:	ithelial gr 3):4300-4	afts in re 308	etinal degenerative
EXAMINER	a	$\int_{\mathcal{U}}$	M	101	'a	,	γ/_	G,	ne	ÜÜ		)	DATE	CONS	IDERED	•		02/	23/	106
EXAMINER: Include a cop	ivipsi it d	tauoi	n co	nsio	erec	ı, wı	1eu	iet of	r not	in coni		nce. [	Oraw line	throug	gh citatio	n only	if not	in conform	nance <u>ar</u>	nd not considered.

SUBSTITUTE (MODIFIED)	FORM	PTO-1	44!	9					EPARTI NT AND					ATTY. PMAN	DOCKET /25	NO.		SERIA 10/667	
								LOSU PLICA						APPLI Gholar	CANT n Peymar				
(37 CFR 1.98	(b))	(	Use	se)	vera	l she	ets if (	neces	sary)						DATE nber 19, 2	:003		GROU 1615	Р
				-					U.S.	PATE	NT DO	осим	ENTS						
EXAMINER INITIAL			PAI	ren	TN	UMB	ER		SSUE DATE		F	PATEN	TEE		CLASS	; [	SUBC	LASS	FILING DATE IF APPROPRIATE
. 4	G.A	$\sqcap$					Τ							<del> </del>					
-	G.B	$\Box$	┪			$\top$	$\top$	╁╌					<u> </u>			7	_		
	G.C	П	Ì	$\exists$		$\top$	$\top$	†								$\top$			
	G.D	T	٦			T	$\top$						_			$\top$			
	G.E	$\Box$			┪	1	$\top$				_					$\top$			
<del> </del>	G.F	П				寸	1												
	G.G G.H G.J																		
	G.H G.I																		
	G.I	G.H G.J																	
•	G.H G.J G.K																		
	G.K	G.J ·																	
-		G.I G.J G.K  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS																	
		G.J  G.K  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  DOCUMENT PUBLICATION COUNTRY OR TRANSL															TRANSLATION (YES/NO)		
	G.L																		
	G.M																		-
	G.N							_					37.2						
	G.O				_	_	1												
	G.P		_																
	G.Q						<u> </u>												
					0	THEF	DOC	UME	NTS (Inc	duding	Autho	or, Title	, Date	, Place o	f Publicat	ion)			
as	G.R	Kara	1001	tu e	t al.	, <u>Lac</u>	k of to	xicity	of Intravi	itreally	admir	nistere	d inter	feron Alp	<u>ha-2a,</u> Or	hthal	mic Su	rger (19	99), 23:833-35
9/8	G.S	Neu	rop	rote	ctio	ı, Pa	rt I: Im	muno	osuppre suppres , pp.3-32	sants,	as Neuro	ologic (	otectiv Disord	ers, and	* Immuno Neuroprot	ection	ressan n, Ed: I	Analogs Borlonga	s in n & Sanberg,
9/8	G.T	Kiryı Isch	u et emi	al., la R	<u>In \</u> epe	/ivo E rfusic	valua n Inju	ition o	f the Inhi	ibitory sentation	Effect on 12	s of Ta 47-B12	crolim 28		06) on Lei 03/199	- \	te Acci	umulatio	n During Retinal
EXAMINER (	Hur	Y0.10	a.	-		B	o-	$\overline{\mathbb{D}}$	)		1	DATE	CONS	IDERED	021	123	3/0	6	
EXAMINER: I	nitial if cit	ation	cor								e. Dra	w line	throug	h citation					d not considered.

																Shee	8(H) Of 15
SUBSTITUTI (MODIFIED)	FORM	PTO-	144	9					.S. DEPART ATENT AND				ATTY. PMAN	DOCKET I /25	NO.	SERI/ 10/66	AL NO. 7,161
									OSURE LICANT				APPLI Gholar	CANT n Peyman			
(37 CFR 1.98	3(b))		(Use	e se	vera	al sh	eets	s if no	ecessary)					DATE nber 19, 20	03	GROU 1615	JP
									U.S	PATEN	r DOCUM	ENTS					
EXAMINER INITIAL			PA <sup>-</sup>	TEN	ПV	UME	BER	·	ISSUE DATE		PATE	NTEE		CLASS	SUB	CLASS	FILING DATE
	H.A															/	
	н.в				Г										1		
·	н.с												/				
	H.D	П										/					
	H.E																
	H.F					П				1							
	H.F H.G H.H H.I																
	H.G H.H																
	H.G H.H H.I H.J																
· /	H.G H.H H.I																
	H.J H.K H.K																
•	H.H H.J																
			DO:	CUN				Pl	UBLICATION DATE	1	COUNT PATENT			CLASS	SUBC	-ASS	TRANSLATION (YES/NO)
	H.L															ı	
	H.M																
	H.N							_									
	H.O				_												
	H.P	_												<del> </del>			
	H.Q																
					0	THE	R D	OCL	MENTS (Inc	Auding A	uthor, Title	e, Date	, Place o	f Publicatio	n)		
0/2	H.R	Lai (					uno	supp	pression prol	ongs sur	ival of RF	E xend	ografts la	beled by re	troviral ge	ne trans	fer, IOVS (9/2000),
ak	H.S	Lalle Biop	ema ohar	nd e	et a ceui	l., <u>C</u> ics,	<u>rdo:</u> 45 (	spori 2003	ine A deliver 3), pp. 307-3	y to the e 18	ye: A pha	maceu	itical cha	<u>llenge,</u> Eur	opean Jou	ımal of P	Pharmaceutics and
08	н.т	Lipn 19ff		Dry	Eye	101	: D	evelo	ping etiolog	ies and tr	eatrments	fort hi	s widesp	read syndro	ome, Eyel	Vorld, Fe	ebruary 1999, pp.
EXAMINER	Sk	υn	W	2	7	10	K	C	al		DATE	CONSI	DERED	(	02/2	3/0(	0
EXAMINER: I	nitial # cit	ation	cor	nside	ered	i, wh	eth	er or	not in confo		Draw line	throug	h citation	only if not	in confor	nance <u>ar</u>	nd not considered.

Sheet 9 (I) of 15

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE (MODIFIED)	FORM	PTO-	144	9										MERCE OFFICE		ITY. VAN/	DOCKE 25	TN	<b>D</b> .		IAL NO 57,161		
			INI ST	FOF	EMA	TIO NT	N D BY	ISCL APP	OSL PLICA	JRE INT							CANT n Peyma	an					
(37 CFR 1.98	(b))		(Us	e se	vera	al sh	eet	s if n	eces	sary)							DATE	200	3	GRO 1615			
										U.	S. P	ATENT	DOC	IMENTS	;								
EXAMINER INITIAL		T	PA	TEN	πN	IUM	BEF	₹		SSUE DATE			PAT	ENTEE	·····		CLAS	ss	SUB	CLASS		FILING DAT APPROPRI	
	I.A																				7		
	I.B	T	Γ	Г					Γ									_					
	I.C	T	Ť													_							
	I.D																						
	I.E	T		Γ							7	_											
	I.F I.G I.H																						
	I.G																						
	I.G																						
	I.F I.G I.H III I.J																						
	I.G I.H																						
	l.K	I.H       I																					
		I.J I.K  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS																					
				CUI				P		ICATIO	ON			NTRY O			CLAS	S	- SUBC	LASS		(YES/NO)	
	I.L		•													1							
	I.M												_								<u> </u>		
	I.N								_										N.				
	1.0				_							<u> </u>									<u> </u>		
	I.P /															_		_			<u> </u>		
	1.Q	L									.,,,										<u> </u>		
					0	THE	R	OOC	UME	NTS (I	Indu	ding A	uthor, T	itle, Dat	e, Pla	ice o	f Public	ation	)				
all	I.R	Lip	per	et a	l., <u>R</u>	ece	nt th	erap	eutic	: adva	nces	in den	natolog	y, JAMA	A, Vol	. 283	3, No. 2,	Jan	uary 12,	2000, p	p, 175-	177	
	I.S	Lop Vis	ez (	et al Scie	, <u>Tr</u>	ansr (19	olan 89).	ted r 30:	etina 586-5	<u>l pigm</u> :88	ent e	pitheli	um moi	tifies the	retin	al de	egenera	tion i	n the R	CS, Inve	st. Oph	ithalmolog	y &
0/8	I.T	Lur rats	nd e g, Pl	t al, NCS	<u>Sut</u>	oretii 001).	nal (	rans (17):	plant 9942	tation o	of ge	netical	ly modi	fied hun	an o	ell lin	es atter	nuate	s loss o	f visual (	unction	n in dystrop	<u>ohic</u>
EXAMINER	. (		lt	h	w	a	٠	) [	J) <sub>l</sub>	lel	Ú	0	DAT	E CONS	SIDEF	RED		0	2/4	23/0	16		
EXAMINER: Include a cop	nitial if c	tation	1 00	nsid	lere	d, w	heth	er o	r not	in con	form		Draw II	ne throu	gh cil	tation	only if	not i	n confor	mance <u>a</u>	ind not	considere	d.

SUBSTITUT (MODIFIED)		PTO-1	149			_		DEPARTA					ATTY	DOCK 1/25	ET N	<b>O</b> .		RIAL I 667,10	
							CLOSI PPLIC							ICANT m Peyr	nan				
(37 CFR 1.9	8(b))	(L	Ise se	ver	al sh	eets i	f neces	isary)						G DATE	-	3	GR0 161	-	
						•		U.S.	PAT	ENT C	OCUM	ENTS							
EXAMINER INITIAL		۶	ATE	NT N	IUM!	BER					PATE	NTEE		CL	ASS	SUB	CLASS	T	FILING DATE IF APPROPRIATE
	J.A		Т							•									
	J.B	$\prod$							T				·					7	
<del></del>	J.C								T										
-	J.D	11													_				
	J.E								1										
	J.F								T	/									
	J.G	Γ	П																
	JA  JB  JC  JD  JE  JF  JG  JH  JJ  JJ  JJ  JJ  JJ  JA  FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS  DOCUMENT PUBLICATION COUNTRY OR																$\top$		
	J.1					7													
-	J.J		7						T										
	J.K												-						
•	J.C  J.D  J.E  J.F  J.G  J.H  J.J  J.J  J.J  J.J  J.J  J.J																		
									Į					CLAS	ss	_SUBC	LASS		TRANSLATION (YES/NO)
	J.L																		
	J.M					$\perp$					_								
	J.N							/											
	J.O					4		······································	$\perp$										
	J.P	_										***							
	J.Q	<u> </u>																	• • •
				0	THE	R DC	CUME	NTS (Inc	dudin	g Auth	or, Titl	e, Date	, Place	of Publi	cation	1)			
0/8	J.R							ect of Ramunology					A in the	Treatr	nent o	of Experi	mental	Autoi	mmune
08	J.S							oxyspergi 36(3):415			devel	pmen	of diab	etes in o	diabet	tes-pron	e BB rat	<u>ts</u> , Sc	andinavian
08	J.T	pp.14	0-14	4					al Ta	acrolim	us, pht	halmic	Surgery	and La	sers,	March/A	\pril 200	02, V	ol. 33, No. 2,
EXAMINER		lun	IN COLOR	٠	$\gamma$	10	)lei	w			DATE	CONS	IDEREC	)	Ĉ	2/2	23/	06	Ó
EXAMINER:	Initial if c	itation	consic	iere	d, W	nethe	r or not	in confor		ce. Dr	raw line	throug	sh citatio	n only i	f not i	in confor	mance	and r	not considered.

																			Sheet	11 (K	<u>)</u> of 1	15
SUBSTITUT (MODIFIED)		PTO-	144	9					S. DEPA						TY. I	OOCKET	NO		SERIA 10/667	L NO.		<u> </u>
									OSURE LICANT						PLIC	ANT Peyman	)					
(37 CFR 1.9	8(b))		(Us	e se	vera	ıl sh	neets	if ne	cessary	)						DATE ber 19, 2	003		GROL 1615	P		
									ı	U.S. P	ATENT	r DOCUI	MENTS									
EXAMINER INITIAL			PA	TEN	IT N	UM	BER	<b>\</b>	ISSU DAT			PATE	NTEE			CLASS	5	SUB	CLASS	FII 	ING DATE	: TE
	K.A																	/				
	к.в	Τ																				
	K.C																					
	K.D																					
	K.E																					
	K.F		Ţ,															_				
	K.G																					
	к.н																					
	K.I																					
	K.J																					
	K.K											·										
•					FO	RE	IGN	PAT	ENTS O	R PUB	BLISHE	D FORE	IGN PA	TEN	IT AF	PLICATI	ONS	3				
				CUI				PI	UBLICAT DATE			COUN PATEN	TRY OF			-etass	1	SUBC	LASS		NSLATIC (ES/NO)	)N
	K.L																					
	K.M																					
	K.N																					
	к.о		ر													_						
	K.P																					
	K.Q																		_			
					0	THE	ER C	ocu	JMENTS	(inclu	ding A	uthor, Ti	tle, Date	e, Pla	ace of	Publicat	ion)					
0/2	K.R	РС	T, <u>I</u>	nterr	natio	mal	Sea	rch F	Report, P	CT/20	04/024	054, ma	iled 07/2	27/04	4, 7 p	g.						
00	K.S	PC	T, <u>J</u>	nterr	natio	nal	Sea	rch F	Report, P	CT/US	503/283	315, mai	iled 06/1	5/04	l, 6 pa	ages						

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

K.T

lunua M. ()

Peyman et al, Keratitis (Noninfectious), Principles and Practice of Ophthalmology, W.B. Saunders Company, 1980, pp.446-

DATE CONSIDERED

02/23/06

SUBSTITUTE (MODIFIED)	FORM F	TO-1	449	)						EPAR NT AN							YTTA NAM		CKE	r NC	).		SER 10/6			
								-	OSU								APPL Ghola		NT eyma	n						
(37 CFR 1.98	(b))	(L	Jse	sev	era	she	ets	if ne	ces	sary)							FILIN Septe		ATE er 19,	200	3		GRC 1615	-		
										U.	S. PA	ATEN	r DO	CUM	ENTS	;										
EXAMINER INITIAL		F	AT	ENT	N	UME	ER			SSUE DATE			P	ATEN	TEE				CLAS	s	SU	IBC	LASS		FILING D	
	L.A																									
-	L.B																					_				
	L.C				I																					
	L.D		1			П										_										
	L.E	П					Т						/													
	L.G L.H																									
	LF LG LH																									
	LE LF LG LH LI																									
	LE LF LG LH																									
	LE  LF  LG  LH  LI  LI  LK															·										
	L.F L.G L.H L.I L.I L.I FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS																									
•		L.F. L.G. L.H. L.I. L.I. L.I. L.K. FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS																								
		Ε		CUM				Pl		CATIC ATE	ON			OUNT!					LASS	;	SUE	3CL	ASS-	-	TRANSLA (YES/N	
	LL																			1						
	L.M																									
	L.N																									
	L.O	-																								
	L.P						T																			
-	ا ال												V 6											$\perp$		
	3.40				0	THE	R D	ocı	JME	NTS (I	nduc	ding A	uthor	r, Title	, Date	e, F	Place	of F	ublica	tion	)					
08	L.R	Peyr 01/0			ula	r So	lutic	ns,	U.S.	Applic	cation	1 Publ	licatio	on No.	2005	5/00	06399	7. ş	ublish	ed (	)3/24/	05,	Serial	No	. 10/752,12	4, filed
6/8	L.S	Peyr	nar	et a	ıl.,	Intra	vitre	al S	urge	ery: Pri	incipl	es an	d Pra	ctice.	2nd E	Edi	tion,	199	4, Aple	eton	& Lar	nge,	CT, p	p. 4	143-452	
ds	LŢ	Peyr 2001	nar	n et a	al., ter	Impl 45, ç	anta	ation 21-5	of a	susta	ined-	releas	se ga	nciclo	vir im	pla	<u>ınt,</u> Vi	trec	retina	l Su	rgical	Tec	upind	es,	Martin Duni	tz Ltd.,
EXAMINER		XII	N	γο.	וח	, 1	1	A)	he	al		)	D	ATE (	CONS	SID	EREC	)		8	2/:	<b>)</b>	3/0	) (	, 2	
EXAMINER: Include a cop	iniuai it ci	ation	$\infty$ r	ISIGE	rec	1, WT	em	er or	not	III CON	IOIII	ance.	Drav	w line	throu	gh	citatio	on c	nly if a	not i	n conf	form	nance	and	not consid	ered.

Sheet 13 (M) of 15 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (MODIFIED) PMAN/25 10/667,161 INFORMATION DISCLOSURE **APPLICANT** STATEMENT BY APPLICANT Gholam Peyman (Use several sheets if necessary) FILING DATE **GROUP** (37 CFR 1.98(b)) September 19, 2003 1615 **U.S. PATENT DOCUMENTS EXAMINER** ISSUE FILING DATE PATENT NUMBER IF APPROPRIATE DATE **PATENTEE CLASS SUBCLASS** INITIAL M.A M.B M.C M.D M.E M.F M.G M.H M.L M.J M.K FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS **DOCUMENT PUBLICATION COUNTRY OR** TRANSLATION SUBCLASS NUMBER DATE PATENT OFFICE CLASS-(YES/NO) M.L M.M M.N M.O M.P M.Q OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) M.R Peyman, Treatment of Ocular Disease, U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

M.R Peyman, Treatment of Ocular Disease, U.S. Application Publication No. 2005/0025810, published 02/03/05, Serial No. 10/631,143, filed 07/31/03

M.S Peyman et al., Intravitreal drug therapy, Japanese Journal of Ophthalmology (1989, 33(4):392-404

M.T Peyman, Treatment of Ocular Disease, U.S. Application Publication No. 2004/0092435, published 05/13/04, Serial No. 10/289,772, filed 11/07/02

EXAMINER

DATE CONSIDERED 02/23/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Q

Sheet 14 (N) of 15 SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE 10/667,161 (MODIFIED) PMAN/25 INFORMATION DISCLOSURE APPLICANT STATEMENT BY APPLICANT Gholam Peyman **FILING DATE GROUP** (Use several sheets if necessary) September 19, 2003 1615 (37 CFR 1.98(b)) **U.S. PATENT DOCUMENTS** FILING DATE **EXAMINER** ISSUE IF APPROPRIATE INITIAL PATENT NUMBER DATE **CLASS** SUBCLASS **PATENTEE** N.A N.B N.C N.D N.E N.F N.G N.H N.I N.J N.K FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS **DOCUMENT PUBLICATION COUNTRY OR** TRANSLATION **BUBCLASS** NUMBER DATE PATENT OFFICE CLASS (YES/NO) N.L N.M N.N N.O N.P N.Q OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Peyman, Ocular Solutions, U.S. Application Publication No. 2005/0063996, published 03/24/05, Serial No. 10/667,161, filed N.R

09/19/03 N.S Revill et al., Genetically Engineered Analogs of Ascomycin for Nerve Regeneration, Journal of Pharmacology and Experimental Therapeutics, Vol. 302:1278-1285 (2002) N.T Shen et al, Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina, Archives of Ophthalmology (7/2001), 119(7):1033-1043

**EXAMINER** 

DATE CONSIDERED

02/23/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

															Sheet	15 (O) of 15			
SUBSTITUTE FORM PTO-1449 (MODIFIED)													MMERCE ATTY. DOCKET NO. PMAN/25			O	SERIAL NO. 10/667,161		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT														APPLICANT Gholam Peyman					
(Use several sheets (37 CFR 1.98(b))									cessary	·)			FILING DATE September 19, 2003			3	GROUP 1615		
										U.S. PAT	CENT C	ОССИМ	ENTS						
EXAMINER INITIAL		PATENT NUMBE						ISSUE R DATE			PATENTEE			CLASS			SUBC	LASS	FILING DATE IF APPROPRIATE
	O.A																	,	
	О.В	T		П		7	7					·····			1				_
	o.c		П																
	O.D						T						/						
	O.E																		
	0.F					T	T												
	0.G					T	J	7											
	0.Н				1	1													
	0.1																		
•	0.1																		
./	0.К																		
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS																			
		DOCUMENT NUMBER						PUBLICATION DATE			COUNTRY OR PATENT OFFICE				CLASS SU		SUBCL	ASS	TRANSLATION (YES/NO)
	O.L																		
	O.M										$\leq$								
	O.N						1												
	0.0			_	_		$\perp$												
	0.P																		
	0.Q			_											<u> </u>				
			,		ОТ	HE	R DO	ocu	MENTS	(Includin	g Auth	or, Title	Date	Place	of Pu	ublication	)		
08	O.R	Sto dial	sic-C betes	Gruji s, C	cic e linica	et al	, <u>Lef</u> Exp	luno: erim	mide pro ental Im	otects mi	ce from y (1999	n multipl 9), 117(*	e low ( I):44-5	dose st i0	repto	zotocin (	MLD-SA)-	induced	insulitis and
Q/8.	O.S									for the T 54,083, fil			у Еуе	, U.S. F	Paten	t Applica	tion Public	cation 20	0030130301,
"WS	O.T	Wa	kele	e-Ly	mch.	Int	erfer	on m	nay offe	r first dru	g thera	ipy for d	iabetic	retino	athy	, Diabete	s Care (1	992), 15	(2):300-301
EXAMINER (	CAMINER Juneia / Reinh DATE CONSIDERED 02/23/06													56					

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.